Breaking News Instant updates and real-time market news.

PTGX

Protagonist Therapeutics

$8.69

0.77 (9.72%)

16:25
11/06/18
11/06
16:25
11/06/18
16:25

Protagonist Therapeutics reports Q3 EPS (38c), consensus (37c)

Reports Q3 revenue $6.12M, consensus $6.43M.

PTGX Protagonist Therapeutics
$8.69

0.77 (9.72%)

03/27/18
BMOC
03/27/18
NO CHANGE
Target $13
BMOC
Outperform
Protagonist Therapeutics price target lowered to $13 from $42 at BMO Capital
BMO Capital analyst M. Ian Somaiya slashed his price target on Protagonist Therapeutics (PTGX) to $13 following the announcement that the company is discontinuing its Phase 2b study of PTG-100 in patients with moderate to severe ulcerative colitis. Somaiya adds that his valuation is now driven by the risk-adjusted sales model for PTG-200, which "represents a higher probability clinical program with peak sales of over $2B". The analyst also notes that he continues to exclude the clinical data of PTG-300 from his model. Despite the steep price target revision, Somaiya keeps his Outperform rating and recommends that investors buy into the weakness after the PTG-100 clinical disappointment on anticipated PTG-200 data and the advancement of Johnson&Johnson (JNJ) - shared Stelara.
06/06/18
LEHM
06/06/18
DOWNGRADE
Target $8.5
LEHM
Equal Weight
Protagonist downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Douglas Tsao downgraded Protagonist Therapeutics to Equal Weight and lowered his price target for the shares to $8.50 from $30. The analyst continues to see value in the company's pipeline assets, but does expect achievement of key catalysts until the second half of 2019. As such, the analyst sees greater near-term potential in small cap names with catalysts upcoming, such as Foamix (FOMX).
08/06/18
LEER
08/06/18
NO CHANGE
Target $21
LEER
Outperform
Protagonist price target raised to $21 after study re-analysis at Leerink
Leerink analyst Joseph P. Schwartz raised his price target on Protagonist Therapeutics shares to $21 from $13 after the company announced results from an independent blinded re-analysis of the Phase 2 PROPEL study of oral alpha-4-beta-7 integrin antagonist PTG-100 for the treatment of patients with ulcerative colitis. He maintains an Outperform rating on Protagonist shares.
08/06/18
LEER
08/06/18
NO CHANGE
Target $21
LEER
Outperform
Protagonist Therapeutics' PTG-100 'back on track,' says Leerink
Leerink analyst Joseph Schwartz says PTG-100 in Ulcerative colitis is "back on track," increasing his confidence in Protagonist Therapeutics' peptide technology platform. The analyst notes that the company reported this morning an unexpected, but very positive, turnaround of its lead program, PTG-100, and will now pursue late-stage clinical development, assuming a positive discussion with the FDA occurs in 2H. While it is unfortunate that the program lost some time when the data set was initially mis-scored and deemed futile when in fact today's news suggests that PTG-100 could have robust clinical efficacy, Schwartz believes that Protagonist's persistence to uncover the truth leading to the resuscitation of the program is positive. The analyst reiterates an Outperform rating on the stock and raised his price target on the shares to $21 from $13.

TODAY'S FREE FLY STORIES

MGA

Magna

$54.61

2.015 (3.83%)

15:04
02/22/19
02/22
15:04
02/22/19
15:04
Downgrade
Magna rating change  »

Magna downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

LTRPA

Liberty TripAdvisor

$16.20

0.31 (1.95%)

15:04
02/22/19
02/22
15:04
02/22/19
15:04
Options
Liberty TripAdvisor options imply 4.8% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.32

0.89 (0.32%)

14:59
02/22/19
02/22
14:59
02/22/19
14:59
Periodicals
U.S. Treasury Secretary says U.S, China reach pact on currency issues, CNBC says »

Steven Mnuchin, U.S.…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.32

0.89 (0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:55
02/22/19
02/22
14:55
02/22/19
14:55
General news
Fed's Bullard doesn't want to be shrinking the balance sheet and cutting rates »

Fed's Bullard…

ALXN

Alexion

$128.46

0.9 (0.71%)

14:52
02/22/19
02/22
14:52
02/22/19
14:52
Hot Stocks
Alexion says FDA grants priority review and accepts sBLA of Soliris »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Mar

14:50
02/22/19
02/22
14:50
02/22/19
14:50
Conference/Events
Senate Energy & Natural Resources Committee to hold a hearing »

The Committee holds a…

JMEI

Jumei

$2.68

0.19 (7.63%)

14:49
02/22/19
02/22
14:49
02/22/19
14:49
Options
Jumei options imply 7.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGR

Avangrid

$48.84

-0.06 (-0.12%)

14:42
02/22/19
02/22
14:42
02/22/19
14:42
Conference/Events
Avangrid to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 04

    Mar

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.77

1.34 (0.48%)

14:42
02/22/19
02/22
14:42
02/22/19
14:42
Periodicals
Xi tells Trump both sides will redouble efforts to come to trade pact, CNBC says »

In a letter to U.S.…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.77

1.34 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRPL

Purple

$5.74

0.045 (0.79%)

14:40
02/22/19
02/22
14:40
02/22/19
14:40
Conference/Events
Purple to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

14:40
02/22/19
02/22
14:40
02/22/19
14:40
General news
Fed's Quarles confirmed the FOMC's decision to maintain an "ample" reserve balance »

Fed's Quarles…

TXN

Texas Instruments

$107.25

0.64 (0.60%)

14:35
02/22/19
02/22
14:35
02/22/19
14:35
Syndicate
Breaking Syndicate news story on Texas Instruments »

Texas Instruments files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

PDVW

pdvWireless

$46.00

5.105 (12.48%)

14:30
02/22/19
02/22
14:30
02/22/19
14:30
Hot Stocks
pdvWireless move higher attributed to FCC proposed rulemaking notice »

Shares of pdvWireless are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NIO

NIO Inc.

$8.01

0.395 (5.19%)

14:25
02/22/19
02/22
14:25
02/22/19
14:25
Options
NIO Inc call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

14:25
02/22/19
02/22
14:25
02/22/19
14:25
General news
Action Economics Survey results: »

Action Economics Survey…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
02/22/19
02/22
14:17
02/22/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
02/22/19
02/22
14:16
02/22/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MUFG

Mitsubishi UFJ

$5.27

-0.02 (-0.38%)

14:15
02/22/19
02/22
14:15
02/22/19
14:15
Hot Stocks
OCC issues cease and desist order against MUFG Bank over BSA violation »

The Office of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

XOG

Extraction Oil & Gas

$4.64

0.83 (21.78%)

14:13
02/22/19
02/22
14:13
02/22/19
14:13
Recommendations
Extraction Oil & Gas analyst commentary  »

Extraction Oil & Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FXI

iShares China Large-Cap ETF

$44.14

0.73 (1.68%)

14:10
02/22/19
02/22
14:10
02/22/19
14:10
Options
Size option spreads in iShares China Fund as the trade-hope rally continues »

Size option spreads in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.82

1.39 (0.50%)

14:09
02/22/19
02/22
14:09
02/22/19
14:09
Periodicals
China, U.S. remain far apart on intellectual property transfer, CNBC reports »

China has committed to…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.82

1.39 (0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRN

Citi Trends

$20.69

0.28 (1.37%)

14:06
02/22/19
02/22
14:06
02/22/19
14:06
Initiation
Citi Trends initiated  »

Citi Trends initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Mar

  • 15

    Mar

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.82

1.39 (0.50%)

14:04
02/22/19
02/22
14:04
02/22/19
14:04
Periodicals
Breaking Periodicals news story on S&P 500, SPDR S&P 500 ETF Trust »

China agrees to buy $1.2…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.82

1.39 (0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNK

Cinemark

$38.52

1.58 (4.28%)

14:04
02/22/19
02/22
14:04
02/22/19
14:04
Recommendations
Cinemark analyst commentary  »

Cinemark Q4 results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 25

    Feb

  • 11

    Mar

  • 02

    Apr

  • 02

    Apr

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$278.82

1.39 (0.50%)

14:04
02/22/19
02/22
14:04
02/22/19
14:04
Periodicals
Breaking Periodicals news story on S&P 500, SPDR S&P 500 ETF Trust »

U.S., China remain far…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$278.82

1.39 (0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.